Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
1992-3-18
|
| pubmed:abstractText |
We screened the antiischemic, hemodynamic, and inotropic effects of different dosages of the new calcium channel blocker Ro 40-5967 in 65 patients with stable effort-induced angina pectoris. In a double-blind way, patients were randomized to recieve a single oral dose of 50, 100, or 200 mg Ro 40-5967 or placebo, given as a drinking solution. Left ventricular ejection fraction (LVEF), blood pressure (BP), and heart rate (HR) were measured at rest and during a supine bicycle exercise test on day 0 (baseline) and 2 h after drug intake on day 1. Twenty-four hours later, the bicycle exercise test was repeated. Ro 40-5967 improved exercise duration and resting LVEF. After 200 mg, exercise time increased significantly from 8.4 +/- 0.8 min (mean +/- SEM) to 9.6 +/- 0.7 min (p = 0.018), and LVEF at rest increased from 54.5 +/- 2.2 to 58.1 +/- 2.6% (p = 0.045). Time to 0.1 mV ST-segment depression increased significantly from 4.3 +/- 0.8 to 5.5 +/- 0.9 min in the 100-mg group (p = 0.013) and from 4.3 +/- 1.3 to 5.4 +/- 1.5 min in the 200-mg group (p = 0.027). Maximum ST-segment depression decreased significantly at all dose levels (p = 0.01), with the maximum decrease noted in the 200-mg group (from 0.21 +/- 0.03 to 0.15 +/- 0.02 mV, p = 0.004). BP, HR, and rate-pressure product did not change significantly at rest or at maximum exercise. A single dose of Ro 40-5967 has antiischemic properties in patients with stable angina pectoris, with maximum effects obtained after 200 mg. No signs of negative inotropy were noted, and the drug was well tolerated.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
0160-2446
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
18
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
N
|
| pubmed:pagination |
746-51
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:1723772-Adult,
pubmed-meshheading:1723772-Aged,
pubmed-meshheading:1723772-Angina Pectoris,
pubmed-meshheading:1723772-Benzimidazoles,
pubmed-meshheading:1723772-Blood Pressure,
pubmed-meshheading:1723772-Calcium Channel Blockers,
pubmed-meshheading:1723772-Coronary Disease,
pubmed-meshheading:1723772-Depression, Chemical,
pubmed-meshheading:1723772-Double-Blind Method,
pubmed-meshheading:1723772-Electrocardiography,
pubmed-meshheading:1723772-Erythrocytes,
pubmed-meshheading:1723772-Exercise Test,
pubmed-meshheading:1723772-Female,
pubmed-meshheading:1723772-Heart Rate,
pubmed-meshheading:1723772-Humans,
pubmed-meshheading:1723772-Male,
pubmed-meshheading:1723772-Mibefradil,
pubmed-meshheading:1723772-Middle Aged,
pubmed-meshheading:1723772-Myocardial Contraction,
pubmed-meshheading:1723772-Radionuclide Ventriculography,
pubmed-meshheading:1723772-Tetrahydronaphthalenes,
pubmed-meshheading:1723772-Ventricular Function, Left
|
| pubmed:year |
1991
|
| pubmed:articleTitle |
Lack of negative inotropic effects of the new calcium antagonist Ro 40-5967 in patients with stable angina pectoris.
|
| pubmed:affiliation |
University Hospital Groningen, The Netherlands.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial
|